BeyondSpring Inc.

BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform. The company's lead asset is Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia (CIN). It also develops Plinabulin in combination with Plinabulin+docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy and radiation; nivolumab, a PD-1 antibody that has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer (ES-SCLC); in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small-molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

BeyondSpring Inc.는 임상 단계 바이오제약 회사로서, 종양학 및 면역학 분야에 중점을 둔 임상 단계 바이오제약 치료제 개발 및 판매에 주력하고 있습니다. 회사는 Plinabulin 파이프라인과 TPD 플랫폼이라는 두 가지 사업 부문을 통해 운영됩니다. 회사의 주요 자산은 선택적 면역 조절 미세소관 결합제인 Plinabulin입니다. Plinabulin은 비소세포폐암(NSCLC) 치료를 위한 3상 임상시험을 완료했으며, 항암제로서 화학요법 유발 호중구 감소증(CIN) 예방 용도로도 개발되고 있습니다. 또한 회사는 비소세포폐암(NSCLC) 및